Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF R egistry
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background and objective: Studies analysing the effect of worsening pulmonary physiological impairment in idiopathic pulmonary fibrosis (IPF) with respect to quality of life have been limited to single centres or highly selected trial populations. The aim of this study was to determine the principal determinants of baseline and longitudinal health‐related quality of life (HRQoL) in a large unselected IPF population. Methods: We used the Australian IPF Registry to examine the relationship between HRQoL, measured using the St George Respiratory Questionnaire (SGRQ), and demographic features, physiological features, co‐morbidities and symptoms. Linear regression analysis was performed to identify predictors of baseline HRQoL, linear mixed model analysis to determine the effect of time and forced vital capacity (FVC) on SGRQ and Cox proportional hazards regression to examine the relationship between HRQoL and all‐cause mortality. Results: Baseline data from 516 patients were available (347 males; mean (SD) age: 71.3 ± 8.6 years). Univariate analysis showed significant associations between HRQoL and demographic, clinical and physiological features. However, multivariate analysis demonstrated independent associations only between SGRQ and dyspnoea (University of California San Diego Shortness of Breathlessness Questionnaire (UCSD‐SOBQ); R 2 = 0.71, P < 0.0001), cough severity (visual analogue scale; R 2 = 0.06, P < 0.0001) and depression (Hospital Anxiety and Depression Scale; R 2 = 0.04, P < 0.0001). Linear mixed‐effects modelling of combined baseline and longitudinal data confirmed these associations, as well as for FVC% predicted (P = 0.005). Multivariate Cox proportionate‐proportional hazards regression analysis demonstrated no association between HRQoL and risk of mortality. Conclusion: Cough, dyspnoea and depression are major symptomatic determinants of HRQoL in IPF. FVC decline is associated with worsening HRQoL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationJones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Wells, A. U., Desai, S. R., Rubens, M. B., Goh, N. S. L., Cramer, D., Nicholson, A. G., Colby, T. V., du Bois, R. M., & Hansell, D. M. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2111053 · Cited by 686
Self-citationA placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Yorke, J., Jones, P. W., & Swigris, J. J. (2010) · Thorax · doi:10.1136/thx.2010.139121 · Cited by 147
Cited by
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Hoffmann-Vold, A.-M., Allanore, Y., Alves, M., Brunborg, C., Airó, P., Ananieva, L. P., Czirják, L., Guiducci, S., Hachulla, E., Li, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217455 · Cited by 357
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
Palliative care in interstitial lung disease: living well
Kreuter, M., Bendstrup, E., Russell, A.-M., Bajwah, S., Lindell, K., Adir, Y., Brown, C. E., Calligaro, G., Cassidy, N., Corte, T. J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30383-1 · Cited by 264
Self-citationKreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0621-y · Cited by 210
Metadata
- Authors
- Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J.
- Venue
- Respirology
- Publisher
- Wiley
- Published
- 2017-02-06
- Volume
- 22
- Issue
- 5
- Pages
- 950-956
- ISSN
- 1323-7799 (ISSN-L)
- 1440-1843
- OpenAlex
- W2586906003
- Cited by
- 123
- References
- 7
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.